Retrospective Analysis for Patients With Metabolic Syndrome

Metabolic Syndrome Clinical Trial

Official title:

Retrospective Analysis of Outpatient Intervention Effects in Patients With Metabolic Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06182618
• Other study ID #: 2023-1042
• Status: Recruiting
• Start date: June 1, 2023
• Est. completion date: January 1, 2024

Study information

• Verified date: November 2023
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: leilei wang
• Phone: 0571-87783851
• Email: 2513118[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The incidence of metabolic syndrome and related diseases is gradually increasing, and diet and medication are currently common outpatient treatment methods. This study retrospectively analyzes the clinical data of patients with metabolic syndrome and related diseases who have visited our outpatient department in the past 10 years, compares the therapeutic effects of different treatment methods on their blood glucose, blood lipids, blood pressure, uric acid, and body composition, and provides evidence support for clinical treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: January 1, 2024
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• individuals who had at least a 2 follow up visits with a BMI of 24 or more with the pri-mary goal of losing weight.

Exclusion Criteria:

• patients did not follow-up on a monthly basis;
• patients followed-up less than 1 times within 3 months;
• patients having incomplete data;
• patients changing their interventions during fol-low-ups

Related Conditions & MeSH terms

• Metabolic Syndrome
• Syndrome

Intervention

Other:
• dietary, semaglutide or/and metformin
patients were prescribed dietary and pharmaceuticals for weight loss

Locations

Country	Name	City	State
China	The Second Affiliated Hospital, College of Medicine, Zhejiang University	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	weight	Weight was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points	0month/1month/2months/3 months
Secondary	visceral fat area(VFA)	VFA was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points	0month/1month/2months/3 months
Secondary	skeletal muscle mass(SMM)	SMM was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points	0month/1month/2months/3 months